文献速递乳腺技术与安全PETCT

局部晚期乳腺癌寡转移性疾病的18F-FDG PET/CT:PETABC试验事后分析

18F-FDG PET/CT of Oligometastatic Disease in Locally Advanced Breast Cancer: PETABC Trial Post Hoc Analysis.
PubMed 文献 · Radiology · 2025-01-01

该研究为前瞻性多中心随机试验的事后分析,纳入369例IIb(T3N0)或III期浸润性导管癌患者,随机接受18F-FDG PET/CT或常规CT加骨显像分期。PET/CT检出寡转移性疾病(≤5个远处转移灶)的比例为11%(19/180),高于CTBS的4%(8/185),P=0.03;PET/CT还检出更多广泛局部区域转移。

要点

  • 18F-FDG PET/CT检出寡转移性疾病的比例为11%(19/180),CTBS为4%(8/185),P=0.03。
  • PET/CT检出多转移性疾病(>5个远处转移灶)的比例为13%(24/180),CTBS为7%(13/185),P=0.04。
  • PET/CT较CTBS更常检出腋外区域淋巴结肿大、区域外淋巴结转移和肝转移,但差异均未达统计学显著。

核心结论

  • 在局部晚期乳腺癌患者初诊分期时,18F-FDG PET/CT可在超过十分之一的患者中检出寡转移性疾病,检出率是CTBS的2.5倍以上,并有助于检出更广泛的局部区域转移性疾病。

研究设计与样本

  • 前瞻性多中心随机试验的事后分析,纳入2016年12月至2022年4月间369例IIb(T3N0)或III期浸润性导管癌患者,随机分配至18F-FDG PET/CT组或常规胸部、腹部、盆腔CT加骨显像(CTBS)组进行分期。

关键影像表现/征象

  • 18F-FDG PET/CT组检出寡转移性疾病19/180(11%,95%CI:6.9,15.9),CTBS组8/185(4%,95%CI:2.2,8.3),P=0.03。
  • 18F-FDG PET/CT组检出多转移性疾病24/180(13%),CTBS组13/185(7%),P=0.04。
  • 在检出寡转移性疾病的患者中,PET/CT组与CTBS组分别有6/19(32%)和1/8(13%)检出腋外区域淋巴结肿大,P=0.63。
  • 在检出寡转移性疾病的患者中,PET/CT组与CTBS组分别有3/19(16%)和0/8(0%)检出区域外淋巴结转移,P=0.53。
  • 在检出寡转移性疾病的患者中,PET/CT组与CTBS组分别有6/19(32%)和1/8(13%)检出肝转移,P=0.63。

诊断标准与关键数值

  • 寡转移性疾病(OMD)定义为五个或更少的远处转移灶。
  • 多转移性疾病定义为超过五个远处转移灶。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background The optimal treatment of patients with oligometastatic breast cancer and the methods for selecting individuals who may benefit from metastasis-directed therapies are controversial. Purpose To determine the prevalence of oligometastatic disease (OMD; defined as five or fewer distant metastases) in patients with locally advanced breast cancer initially staged at fluorine 18 (18F) fluorodeoxyglucose (FDG) PET/CT or at CT and bone scintigraphy (CTBS), and to compare patterns of local-regional and distant metastatic disease. Materials and Methods This is a post hoc analysis of data from a prospective, multicenter randomized trial including participants with stage IIb (T3N0) or III invasive ductal carcinoma in the breast between December 2016 and April 2022. Participants were randomized for staging at 18F-FDG PET/CT or at conventional chest, abdomen, and pelvis CTBS. The prevalence of OMD, sites of distant metastases, and extent of local-regional disease were compared using the χ2 test or Fisher exact test. Logistic regression was used to assess the association between imaging and disease extent, with P < .05 indicating a statistically significant difference. Results The study included 369 participants (mean age, 53 years ± 13 [SD]). OMD was more common on 18F-FDG PET/CT scans (19 of 180; 11%; 95% CI: 6.9, 15.9) than on CTBS scans (eight of 185; 4%; 95% CI: 2.2, 8.3; P = .03). Polymetastatic disease (more than five distant metastases) was also more common on 18F-FDG PET/CT scans (24 of 180; 13%) than on CTBS scans (13 of 185; 7%; P = .04). Patients with OMD that was depicted on 18F-FDG PET/CT and CTBS scans had axillary lymph node metastases, but 18F-FDG PET/CT helped to detect extra-axillary regional lymphadenopathy, extra-regional lymph node metastases, and liver metastases more frequently than did CTBS (six of 19 [32%] vs one of eight [13%], three of 19 [16%] vs 0 of eight [0%], and six of 19 [32%] vs one of eight [13%], respectively; P = .63, .53, and .63, respectively). Conclusion At patient presentation, 18F-FDG PET/CT helped to detect OMD in more than one in 10 participants with locally advanced breast cancer, which was more than 2.5 times more often than CTBS, and 18F-FDG PET/CT helped to detect more extensive local-regional metastatic disease. ClinicalTrials.gov Identifier: NCT02751710 © RSNA, 2025 Supplemental material is available for this article. See also the editorial by Ulaner in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Metser U, Ali Mirshahvalad S, Dayes IS, et al. 18F-FDG PET/CT of Oligometastatic Disease in Locally Advanced Breast Cancer: PETABC Trial Post Hoc Analysis. Radiology. 2025. PMID: 40762843. doi:10.1148/radiol.243788

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。